cause of disability and excess mortality in older women. Estrogen therapy has been used for treatment and prevention of osteoporosis; however, many older women are reluctant to use it because of adverse effects. Recent data from the Women's Health Initiative demonstrated that postmenopausal women who took hormone therapy for approximately 7 years had decreased hip fracture risk; however, the dose and preparation of hormone therapy used in the study also increased the risk of breast cancer, heart disease, stroke, and deep venous thrombosis.
METHODS
Healthy, community-dwelling women who were older than 65 years were recruited to participate in the study. The exclusion criteria were (1) diseases or medications affecting bone metabolism; (2) use of estrogen or calcitonin within the past 6 months; (3) ever use of bisphosphonates or fluoride; (4) history of breast or endometrial cancer within the past 5 years; (5) baseline endometrial thickness greater than 5 mm; (6) any thromboembolic event within 6 months; and (7) bone mineral density (BMD) t score of less than −4; or (8) symptomatic vertebral fracture within the past year or past history of low trauma hip fracture. White women were recruited by newspaper advertisement or by letter of invitation from existing databases. Black and Hispanic women were recruited through community presentations on osteoporosis and BMD screening sessions.
The institutional review board at the University of Connecticut Health Center approved the study, and all women provided written informed consent. Eligible women were randomly assigned to treatment with 0.25 mg/d of 17␤-estradiol or placebo using a computergenerated list. The research pharmacist maintained the randomization list; all other staff members, as well as all participants, were blinded to treatment allocations. All women who had not had a hysterectomy received 100 mg/d of micronized progesterone for 2 weeks every 6 months. All participants received 1300 mg/d of elemental calcium and 1000 IU/d of vitamin D. The primary outcome was BMD of the hip, which was measured at baseline and then annually for 3 years. We also evaluated spine, wrist, and total body BMD. Serum and urine markers of bone turnover and sex hormones (estradiol, estrone, and sex hormone-binding globulin [SHBG] ) were measured at baseline, 3 months, and during years 1 and 3 of treatment. Dietary calcium intake was estimated at baseline and then yearly using a 4-day food diary. Physical activity was assessed at baseline and then yearly using the Physical Activity Scale for the Elderly. 8 Adverse effects were assessed by questionnaire using a Likert scale and by diary completion. Endometrial thickness was measured by transvaginal ultrasound at baseline and every 6 months prior to progesterone administration. We completed endometrial biopsies in women with endometrial thickness of 8 mm or greater and asked all women to undergo endometrial biopsy at the 3-year visit. Women had annual mammograms while enrolled in the study. We measured adherence to calcium intake and study medication using pill counts every 3 months. Bone density was measured by dualenergy x-ray absorptiometry (Lunar DPXL, Madison, Wis). The coefficient of variation of BMD measurement, based on reproducibility scans completed in women older than 65 years, are 1.3% for femoral neck; 1.1%, total hip; 1.7%, L1-L2 spine; 2.2%, L2-L4 spine; 3.7%, ultradistal wrist; 1.3%, 33% radius; and 0.5%, total body.
Fasting serum and urine samples were collected between 7 AM and 9:30 AM and stored at −80°C. Bone marker assays were run in duplicate after one thaw; all samples for one individual were assayed using the same kit. We measured bone alkaline phosphatase (Metra Biosystems Inc, Mountain View, Calif ) and urinary crosslinked Ntelopeptides (Ostex International Inc, Seattle, Wash) using enzyme-linked immunosorbent assay. Intra-assay variability was 8% for N-telopeptides and 5% for bone alkaline phosphatase. We measured estradiol and estrone using radioimmunoassay and SHBG using immunoradiometric assay (Diagnostic Systems Lab Inc, Webster, Tex). The intraassay variability for these studies in the general clinic research center laboratory is lower than 10%. The detection limit of the estradiol assay is 2 pg/mL. The level of 25-hydroxyvitamin D was measured by competitive protein binding (Esoterix Inc, Calabasas, Calif).
Baseline and clinical characteristics are reported using means and SDs stratified by treatment group. We tested for the difference in baseline characteristics between the treatment groups using 1-way analysis of variance and 2 analysis. We tested for normality of distribution of all variables and none required transformation. We analyzed the primary outcome data using mixed models procedural software (SAS PROC MIXED, SAS Institute Inc, Cary, NC). The dependent variables were BMD measurements at baseline, and at 1, 2, and 3 years. The fixed effects were treatment group, time, and treatment group time interaction. The random effects were individual subjects as well as time nested within subject. The main variable of interest was the treatment group time interaction term, which demonstrated whether the changes in BMD were different in the 17␤-estradiol treatment group compared with placebo. We completed a separate analysis for each BMD site. We estimated the difference in absolute and percentage BMD change between placebo and treatment group at 3 years and report these for women who completed the study. To account for 
RESULTS
The baseline characteristics of the 167 women included in the study from July 24, 1998, through June 14, 2002 , and randomized to treatment are listed in TABLE 1 and TABLE 2. Baseline characteristics did not differ significantly between groups except for activity level on the Physical Activity Scale for the Elderly, which was higher in the 17␤-estradiol treatment group (P=.02). Over the 3-year study period, 31 women (36%) discontinued participation in the placebo group and 24 (29%) in the 17␤-estradiol group (FIGURE 1) . Adherence was the same for both groups and ranged from 87% to 94% for study medication and 78% to 92% for calcium supplementation (compliance over 3 years and checked every 3 months).
Low-dose estrogen significantly increased bone density at all BMD sites compared with placebo (TABLE 3 and FIGURE 2). Controlling for age, weight, and height did not change our findings, although the placebo group had a 2% weight loss (67.2 kg at baseline to 65.9 kg at 3 years) while the 17␤-estradiol group remained stable (68.5 kg at baseline to 68.3 kg at 3 years). Women who received progesterone had similar BMD changes as women who did not. Compared with the placebo group, participants who received 17␤-estradiol treatment had significantly decreased markers of bone turnover (TABLE 4). In the 17␤-estradiol treatment group, crosslinked N-telopeptides of type 1 collagen, a marker of bone resorption, decreased 28% at 3 months, 43% at 1 year, and 24% at 3 years compared with placebo. The difference in the change in crosslinked N-telopeptides of type 1 collagen between placebo and 17␤-estradiol treatment was statistically significant at all time points. The bone alkaline phosphatase level decreased significantly in the treatment group compared with the placebo group at 1 year and 3 years, but not at 3 months (P=.79). Estrone and estradiol levels increased significantly (PϽ.001) in the treatment group compared with the placebo group (Table 4) . Both mean estradiol and estrone levels increased in the treatment group by 3 months and then remained constant for the duration of the study. Levels of SHBG increased by 13% in participants after 3 years of treatment compared with the placebo group. Because of the large increase in estrone and estradiol levels and the relatively smaller change in SHBG, the free estrogen index (17␤-estradiol + estrone/ SHBG) increased over time.
Endometrial thickness increased slightly in both groups over the 3-year study but there was no significant difference between groups except at year 2 (TABLE 5). Over 3 years, 5 women reported bleeding in the 17␤-estradiol group. Three women reported scheduled bleeding after taking progesterone and 2 reported unscheduled bleeding. Of the 2 women with unscheduled bleeding, one had 3 episodes of spotting within 4 months of her 18-month visit and the other had 1 week of bleeding prior to her 6-month visit and then again following an endometrial biopsy at 12 months. There was no statistically significant dif- ference in endometrial biopsy categories between the 2 groups. Four women (3 in the 17␤-estradiol group and 1 in the placebo group) required interim endometrial biopsies. Of these women, 1 woman (in the 17␤-estradiol group) had 4 biopsies-2 biopsies showed atrophic endometrium and 1 showed hyperplastic endometrium; the final biopsy (after progesterone treatment for hyperplasia) demonstrated atrophic endometrium. Another woman (in the placebo group) had hyperplasia and was treated; the repeat biopsy demonstrated atrophic endometrium, but she dropped out of the study. The other 2 women in the 17␤-estradiol group had proliferative endometrial tissue on one biopsy and atrophic endometrium on the final biopsy. One additional woman had weakly proliferative endometrium on the final biopsy with an endometrial thickness of 9 mm. By 2 analysis, breast tenderness, fluid retention, bloating, and headache were not significantly different between the groups (Table 5 ) except more headaches were reported in the placebo group at 3 years. There was no significant difference in the total number of abnormal mammogram results (n=15 in the 17␤-estradiol group vs n=10 in the placebo group; P=.26) or in the number of abnormal follow-up mammogram results (n = 12 in 17␤-estradiol group vs n=5 in placebo group; P=.07). One woman in the 17␤-estradiol group dropped out of the study secondary to an abnormal mammogram result at 6 months. There were no reports of breast cancer during the study.
The number of low trauma fractures was higher in the placebo group than in the 17␤-estradiol group, but there were only 8 incident fractures. The placebo group had 2 wrist, 1 patella, 1 rib, and 2 hand/finger fractures while the treatment group had 1 humerus and 1 hand/ finger fracture. There were no symptomatic vertebral or hip fractures.
COMMENT
Our study demonstrates that 0.25 mg/d of 17␤-estradiol increased BMD at the hip, spine, and wrist and decreased markers of bone turnover in older women. The long-term adverse effect profile of this dose of estrogen was similar to placebo. These data suggest that this low dose of estrogen had a beneficial effect on bone without the adverse effects typically associated with estrogen therapy. These data confirm and expand our previous study, which demonstrated an equivalent short-term effect with dosages of 0.25 mg/d, 0.5 mg/d, and 1.0 mg/d of 17␤-estradiol on markers of bone turnover. 7 The dose of estrogen used in this study was equivalent to 0.15 mg/d of CEE or one quarter of the usual estrogen dose and half the dose used in previous studies in older women. 6 4 Previous studies, conducted in younger postmenopausal 14 This study is the first, to our knowledge, to examine an ultralow estrogen dose in a long-term randomized placebo-controlled study.
The increase in BMD, compared with placebo, in the current study (femoral neck 2%, total femur 4%, lumbar spine 3%) are somewhat smaller than BMD changes seen with antiresorptive agents that have been shown to reduce fractures in postmenopausal women. [15] [16] [17] However, most fracture studies were completed in postmenopausal women with established osteoporosis (t score Ͻ −2.5 or presence of vertebral fracture at baseline) who were younger than women in the current study. In the only prospective study of BMD and fracture using estrogen, Lufkin et al 15 reported decreased vertebral fracture risk after 1-year treatment with transdermal 17␤-estradiol plus medroxyprogesterone acetate with a relative risk of 0.39; the mean increase in lumbar spine BMD, compared with placebo, was 5%. In a 3-year study of raloxifene on vertebral fracture risk, the increase in lumbar spine *Intention-to-treat analysis used Gaussian linear mixed models to account for missing data; absolute difference between groups is adjusted. †Dosage of 0.25 mg/d. ‡Adjusted for height, weight, and age.
17␤-ESTRADIOL AND BONE DENSITY BMD was 2.6% compared with placebo and this was associated with approximately 30% reduction in new vertebral fractures; the incidence of nonvertebral fractures did not decrease with raloxifene. 16 Risedronate treatment resulted in BMD increases of 4.3% and 2.8% for the lumbar spine and femoral neck, respectively; these changes were associated with a 41% decrease in new vertebral fractures and a 39% decrease in nonvertebral fractures. 17 The initial alendronate study 18 reported somewhat larger BMD changes, however a later study in women with low BMD without prevalent vertebral fractures over 3 years were more comparable with the current study (femoral neck 3%, total femur 4%, lumbar spine 6%). 19 In the latter study, fracture reduction only occurred in the subset of women with osteoporosis by BMD. Given the different populations involved in the studies, it is difficult to predict whether BMD changes in the current study will result in decreased fracture rates. Nonetheless, the BMD changes seen in this study are comparable with changes seen in fracture studies of approved agents for prevention and treatment of osteoporosis, particularly raloxifene and risedronate.
The change in markers of bone turnover is consistent with BMD changes. Ntelopeptides, a marker of bone resorption, decreased within 3 months in participants receiving 17␤-estradiol treatment while bone alkaline phosphatase levels did not decrease until 1 year. This is similar to previous studies of 17␤-estradiol that demonstrated an immediate effect of 17␤-estradiol on bone resorption with a later effect on bone formation, presumably due to coupling of bone formation and resorption. 3, 4, 7, 12 Furthermore, while estrogen increased estradiol and estrone levels, it had little effect on SHBG levels, resulting in an increased free estrogen index over time.
Cummings et al [20] [21] [22] reported that women with undetectable levels of endogenous estradiol (Ͻ5 pg/mL) had an increased risk for bone loss and fracture. Women with estradiol levels lower than 5 pg/mL experienced 0.8% per year Abbreviations: BCE, bone collagen equivalents; CI, confidence interval.
*Dosage of 0.25 mg/d. †Intention-to-treat analysis used Gaussian linear mixed models to account for missing data; absolute difference between groups is adjusted. bone loss at the hip, while those with levels higher than 10 pg/mL experienced only 0.1% per year loss. In the same study, high SHBG levels were also associated with increased bone loss at the hip. Our study demonstrates that low-dose estrogen, which increased estradiol and estrone, with a smaller effect on SHBG, had a beneficial effect on bone at all important fracture sites. Our 3-year intervention study supports the epidemiological data from the Study of Osteoporotic Fractures [20] [21] [22] that estradiol levels need not be in the premenopausal range to protect bone and suggests that the usual dose of estrogen may increase adverse effects with minimal additional benefit to bone.
The adverse effect profile in the 17␤-estradiol treatment group in our study was similar to placebo, confirming the tolerability of low-dose estrogen over 3 years. We used lower dose progesterone every 6 months and that regimen protected the endometrium of women who had not had a hysterectomy, although further studies are required to fully determine the safety of this progesterone dose. Only 2 women (one in each group) had endometrial hyperplasia on biopsy and both of these women had increased endometrial thickness. The reasons for discontinuation were similar in both groups suggesting that low-dose estrogen did not result in adverse health outcomes for older women.
This study has limitations. It is a fairly small randomized controlled study with the primary outcome of BMD. The length of the study is similar to previous studies in this population but was neither long enough nor large enough to discern the effect of low-dose estrogen on fracture incidence or major adverse effects such as cardiovascular disease, stroke, or breast cancer. However, despite these limitations, the positive effect on BMD is promising. The preparation of estrogen used was 17␤-estradiol while most previous studies used CEE. Conjugated equine estrogen and 17␤-estradiol may not have the same effects on bone or produce the same adverse events, although studies have not directly compared these 2 different estrogen preparations. In a previous 3-year study using 0.3 of mg/d of CEE plus 2.5 mg/d of MPA in older women, the adverse effect profile was also favorable. 6 This study demonstrates that 0.25 mg/d of 17␤-estradiol increased BMD at important fracture sites and decreased bone turnover in older women with minimal adverse effects. The data from the Women's Health Initiative regarding the potential adverse effects of hormone therapy are a concern. However, our study supports a beneficial effect of lower dose estrogen on BMD and we hypothesize that lowering the dose of estrogen may also reduce the number of adverse events over a longer study period. Because BMD is an intermediate outcome, studies of fracture incidence are essential to fully evaluate the use of ultralow-dose estrogen in older women. 
